Blog

The market risk premium is going down...

The market risk premium is going down...

It will still be beautiful, it will still be normal... And there are already the first signs.

Duff & Phelps has lowered its recommended Equity Risk Premium for the U.S. market from 6.0% to 5.5% for estimating the cost of capital as of December 9, 2020. The market risk premium is one of the most important parameters necessary to estimate the cost of capital in the Capital Asset Pricing Model (CAPM), used in the processes of valuation of companies and companies.

What factors led D&P to recommend an ERP downgrade?

The most important of them are:

  • Record level of stock prices on US stock exchanges in the fourth quarter of 2020;
  • Optimism stemming from the arrival of a COVID-19 vaccine;
  • Expected further support from the Fed implying a low level of interest rates;
  • Reduced uncertainty related to the impact of the US presidential election results on the economy and corporate performance.

In addition, US stock price volatility has returned to close to long-term averages, corporate credit spreads have declined to historical averages, consumer confidence and business confidence have improved (albeit still below pre-COVID-19 levels). Of course, there are also risk factors...

To be clear, after the outbreak of the pandemic (25 March 2020) D&P raised its recommended market risk premium from 5.0% to 6.0%. That is, after the reduction, we are halfway to pre-pandemic conditions.

It is also worth noting that the normalized risk-free rate (Rf) is assumed by D&P at 2.5%, which implies a base cost of equity for the US market of 8.0%.

The main question is whether this wave of optimism will also come to Poland...

Image

Value Solutions

Cann Advisory sp. z o.o.

Plac Jana Henryka Dąbrowskiego 1

00-057 Warsaw

tel. +48 22 616 20 32

mob. +48 606 234 150

e-mail info@cann.pl

Cann.pl - Wycena firm, spółek, wartości niematerialnych i prawnych

PL EN

Cann Advisory sp. z o.o.
Plac Jana Henryka Dąbrowskiego 1
00-057 Warsaw
phone +48 22 616 20 32
mob. +48 606 234 150
info@cann.pl